Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02 2018 - 4:05PM
Business Wire
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical
company focused on delivering innovative therapies to patients with
kidney disease through the biology of hypoxia-inducible factor
(HIF), granted four newly-hired employees options to purchase an
aggregate of 25,400 shares of Akebia’s common stock on October 31,
2018, as inducements material to each such employee’s entering into
employment with Akebia. The options were granted in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $7.49 per share,
which is equal to the closing price of Akebia’s common stock on the
grant date. Each stock option vests over four years, with 25% of
the shares vesting on the first anniversary of the grant date and
the remaining 75% of shares vesting quarterly thereafter, in each
case, subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of the company’s Inducement Award Program and
a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company
headquartered in Cambridge, Massachusetts, focused on
delivering innovative therapies to patients with kidney disease
through hypoxia-inducible factor biology. For more information,
please visit our website at www.akebia.com, which does not
form a part of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181102005009/en/
Akebia TherapeuticsJohn Garabo, 617-844-6130Director,
Corporate Communicationsjgarabo@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2023 to Apr 2024